The “OPTI-CLOT” trial^[*]

Summary

Haemophilia A is an X-linked inherited, rare bleeding disorder, caused by a deficiency of coagulation factor VIII (FVIII). Previous studies in prophylactic dosing have demonstrated that FVIII consumption can be significantly reduced by individualising dosing based on combined analysis of individual pharmacokinetic (PK) profiling and population PK data (Bayesian analysis). So far, no studies have been performed that address perioperative concentrate consumption using iterative PK-guided dosing based on a PK population model. The “OPTI-CLOT” trial is an open-label, prospective, multicentre randomised controlled superiority trial (RCT), aiming to detect a 25 % difference in perioperative FVIII concentrate consumption with iterative Bayesian PK-guided dosing in comparison to the standard dosing procedure. Sixty haemophilia A patients ≥ 12 years of age, with FVIII plasma levels ≤0.05 IUml^-1 will be included requiring FVIII replacement therapy administered either by continuous or bolus infusion for an elective, low or medium risk surgical procedure. The proposed study aims to investigate a novel perioperative iterative PK-guided dosing strategy, based on a recently constructed perioperative PK population model. This model will potentially decrease underdosing and overdosing of clotting factor concentrate and is expected to overall reduce FVIII consumption by minimally 25 %. Moreover, participating hospitals will gain experience with PK-guided dosing, facilitating future implementation of this intervention which is expected to optimise current care and reduce costs of treatment.

This study is part of the “OPTI-CLOT” research programme (Patient tailOred PharmacokineTIc-guided dosing of CLOTting factor concentrates in clotting disorders)”, an (inter)national multicentre study aiming to implement PKguided dosing of clotting factor replacement therapy by initiating studies to demonstrate its implications and feasibility, improve PK models and to increase knowledge of patient-tailored PK-guided dosing.

Keywords

Haemophilia therapy - factor VIII - factor concentrates - pharmacokinetics - Bayesian analysis

^* Trial registration: NTR4121.

• References

• 1 Johnson KA, Zhou ZY. Costs of care in haemophilia and possible implications of health care reform. Hematology Am Soc Hematol Educ Program 2011; 2011: 413-418.
• 2 Schramm W, Berger K. Economics of prophylactic treatment. Haemophilia 2003; 09 (Suppl. 01) 111-116.
• 3 Feldman BM, Aledort L, Bullinger M. et al. The economics of haemophilia prophylaxis: governmental and insurer perspectives. Proceedings of the Second International Prophylaxis Study Group (IPSG) symposium. Haemophilia 2007; 13: 745-749.
• 4 Leebeek FWG, Mauser-Bunschoten EP. Richtlijn Diagnostiek en behandeling van hemofilie en aanverwante hemostasestoornissen. Van Zuiden Communications BV 2009; 1-197.
• 5 Lock J, Hazendonk HCAM, Bouzariouh H. et al. A retrospective observational multicenter cohort study on peri-operative Factor VIII consumption in haemophilia A (“OPTI-CLOT” studies). J Thromb Haemost. 2013 11. 2 Abstract PB 2.36–2.
• 6 Hazendonk HCAM, Lock J, Fijnvandraat K. et al. A retrospective observational multicenter study on peri-operative Factor IX consumption in haemophilia B (“OPTI-CLOT” studies). J Thromb Haemost 2013 11. (Suppl 2): Abstract PA 2.07–1.
• 7 Collins PW, Fischer K, Morfini M. et al. International Prophylaxis Study Group Pharmacokinetics Expert Working G. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17: 2-10.
• 8 Bjorkman S. Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A. Haemophilia 2010; 16: 597-605.
• 9 Carlsson M, Berntorp E, Björkman S. et al. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemophilia 1997; 03: 96-101.
• 10 Longo G, Messori A, Morfini M. et al. Evaluation of factor VIII pharmacokinetics in haemophilia-A subjects undergoing surgery and description of a nomogram for dosing calculations. Am J Hematol 1989; 30: 140-149.
• 11 Batorova A, Martinowitz U. Continuous infusion of coagulation factors: current opinion. Curr Opin Hematol 2006; 13: 308-315.
• 12 Batorova A, Martinowitz U. Intermittent injections vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery. Br J Haematol 2000; 110: 715-720.
• 13 Srivastava A. Choice of factor concentrates for haemophilia: a developing world perspective. Haemophilia 2001; 07: 117-122.
• 14 Dingli D, Gastineau DA, Gilchrist GS. et al. Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates. Haemophilia 2002; 08: 629-634.
• 15 Mulcahy R, Walsh M, Scully MF. Retrospective audit of a continuous infusion protocol for haemophilia A at a single haemophilia treatment centre. Haemophilia 2005; 11: 208-215.
• 16 Negrier C, Lienhart A, Meunier S. Surgeries in patients with haemophilia A performed with a continyous infusion of Recombinate. J Thromb Haemost 2001; Suppl 1-P0829.
• 17 Stieltjes N, Altisent C, Auerswald G. et al. Continuous infusion of B-domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experience. Haemophilia 2004; 10: 452-458.
• 18 Perez Bianco R, Primiani L, Neme D. et al. Continuous infusion of factor VIII for major orthopedic surgery in persons with haemophilia A. Haemophilia 2004; 10 (Suppl. 03) PO38.
• 19 Bidlingmaier C, Deml MM, Kurnik K. Continuous infusion of factor concentrates in children with haemophilia A in comparison with bolus injections. Haemophilia 2006; 12: 212-217.
• 20 Batorova A, Martinowitz U. Continuous infusion of coagulation factors. Haemophilia 2002; 08: 170-177.
• 21 Hazendonk HCAM, Lock J, Fijnvandraat K. et al. Population pharmacokinetics in haemophilia A: Towards individualization of perioperative replacement therapy. Bari International Conference Abstract book 2014 PO.04. 17-91. http://www.bic2014.org/wp-content/uploads/2014/10/BIC2014_abstract_book.pdf
• 22 Koshy M, Weiner SJ, Miller ST. et al. Surgery and anesthesia in sickle cell disease. Cooperative Study of Sickle Cell Diseases. Blood 1995; 86: 3676-3684.
• 23 Hakkaart-van Roijen L, Tan SS, Bouwmans CAM. Handleiding voor kostenonderzoek: Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. Instituut voor Medical Technology Assessment Erasmus Universiteit Rotterdam 2010; 1-127.